Highlights
1.
Impli, Yalosys, and CSEM unite to advance an implantable biosensor, CERES, for real-time fertility hormone monitoring.
2.
Amidst increasing infertility rates and the high costs of in vitro fertilization (IVF) treatments, CERES emerges as a more accessible solution.
3.
Engineered to offer a safer and more efficient method for managing fertility, CERES is a 21-months endeavor backed by Innosuisse set to develop a state-of-the-art medical device.
Additional information
CSEM
Samantha Paoletti
Head R&BD, Life Science Technologies
T. +41 81 307 81 60
samantha.paoletti@csem.ch
Impli Limited
Anna Luisa Schaffgotsch
Founder & CEO
T +44 77 433 479 08
info@impli.org
Yalosys
Luigi Calabrese
Co-Founder & CEO
T +41 76 284 60 36
luigi.calabrese@yalosys.com
CSEM Media Relations
Sabina Müller
Media Relations
T. +41 79 361 50 12
media@csem.ch
About Impli Limited
Impli is a biotech company founded in April 2019 to make people’s lives safer and healthier using implantable technology. Impli’s vision and strategy are pivoted to the future of implantables, through the development of a range of innovative products to enable real-time, hassle-free access to your health condition data from the tip of your smartphone. The first of these products is a new generation implantable in the fertility space to better monitor the female going through IVF and hopefully reduce the number of cycles needed for a successful pregnancy. It has already been featured in the Octopus Ventures Future of Fertility Report.
About Yalosys
Yalosys AG is a privately owned Swiss SME focused on providing laser micro processing solutions for “IN GLASS” product manufacturing: from the single glass component to the fully packaged microsystem. We provide laser micromachining services for small to mid-volume productions, contract service manufacturing for the development of new “IN GLASS” products as well as engineering & consultancy services to support our customers in the development of new projects, compliant with the regulations and best practices (GMP, ISO 13485) of the MedTech sector.
Related Press
31 May 2023
CSEM collaborates with innovative Swiss start-up MOMM Diagnostics to introduce revolutionary preeclampsia test
A cutting-edge point-of-care solution for preeclampsia diagnostics has been developed by the two partners: the system resembles a pregnancy test with electronic result analysis and allows a rapid diag...
4 May 2021
Aktiia: optical blood pressure monitoring
As of today, Aktiia’s connected 24/7 OBPM system is available in Switzerland, Austria, France, Germany, and Ireland. The groundbreaking medical innovation provides users and physicians with comprehens...
11 January 2021
Biospectal Announces Public Beta Launch Of OptiBP™
Biospectal’s OptiBP smartphone app and data platform empowers people worldwide with a medical-grade device integrated directly into their smartphone, enabling instantaneous blood pressure measurement ...